Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model-Reference-Cited by-同舟云学术

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 2: Investigating Interaction Potential Using a Physiologically Based Pharmacokinetic Model

Published:2020-04-27 Issue:9 Volume:59 Page:1149-1160
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Van den Bergh An,Snoeys Jan,De Zwart Loeckie,Ward Peter,Lopez-Gitlitz Angela,Ouellet Daniele,Monshouwer Mario,Chien Caly

Funder

Janssen Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-020-00881-3.pdf

Reference41 articles.

1. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–503.

2. ERLEADA (apalutamide) [prescribing information]. Horsham, PA: Janssen Pharmaceutical Companies; 2019.

3. ERLEADA [summary of product characteristics]. The electronic Medicines Compendium (eMC). Available at: https://www.ema.europa.eu/en/documents/product-information/erleada-epar-product-information_en.pdf. Accessed 4 Oct 2019.

4. Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 2013;19(1):43–9.

5. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408–18.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments;Critical Reviews in Oncology/Hematology;2024-08

2. Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer;The Prostate;2024-06-18

3. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact;Expert Opinion on Drug Metabolism & Toxicology;2024-05-22

4. Review of drug-drug interactions in patients with prostate cancer;Journal of Oncology Pharmacy Practice;2024-05-08

5. Bioequivalence of 240 mg Apalutamide Tablets and Preparation in Aqueous Food Vehicles for Alternative Administration;Clinical Pharmacology in Drug Development;2023-11-20